查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859214

肺癌診斷市場報告：趨勢、預測和競爭分析（至2031年）

Lung Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球肺癌診斷市場前景廣闊，在工業和醫療保健領域均蘊藏著巨大機會。預計2025年至2031年，全球肺癌診斷市場將以5.7%的複合年成長率成長。推動該市場發展的關鍵因素包括全球肺癌發病率的上升、非侵入性液態切片的日益普及以及人工智慧成像技術的廣泛應用。

  • Lucintel 預測，在預測期內，分子檢測將成為成長最快的檢測類型。
  • 從應用領域來看，醫療保健產業預計將呈現高速成長。
  • 從區域來看，預計亞太地區在預測期內將達到最高成長。

肺癌診斷市場的新趨勢

在基因組學、影像學和人工智慧等技術的進步推動下，肺癌診斷市場目前正經歷著重大變革。這些新興趨勢將顯著提高肺癌診斷的準確性、可近性和個人化程度，最終改善患者的治療效果。

  • 液態切片的應用：液態切片透過分析血液中的循環腫瘤DNA（ctDNA）和其他生物標記物，正迅速成為新興趨勢。這種非侵入性方法為組織切片檢查提供了一種創傷更小的替代方案，能夠實現更早期的腫瘤檢測、治療反應監測和抗藥性機制識別，從而徹底改變患者管理。
  • 人工智慧和機器學習在診斷成像中的應用：將人工智慧 (AI) 和機器學習 (ML) 整合到診斷成像（電腦斷層掃描、X 光片）中是一種強勁的發展趨勢。 AI 演算法能夠增強對細微結節的檢測，減少假陽性結果，提高診斷準確率，並幫助放射科醫生高效分析大量影像數據，從而實現更早、更準確的診斷。
  • 多組體學分析：目前，結合基因組學、蛋白質組學和代謝組學數據進行肺癌全面診斷的多體學分析正成為日益流行的趨勢。這種整合方法能夠辨識複雜的分子特徵，更精確地對患者進行分層，並指導高度個人化的治療策略，從而獲得更佳的治療效果。
  • 照護現場診斷：快速、便攜、易用的即時診斷（POC）設備的開發正成為一種新興趨勢，尤其是在生物標記檢測領域。這些設備能夠在非專業環境下進行快速篩檢和初步診斷，從而提高偏遠和資源匱乏地區的診斷可及性。
  • 遠端醫療整合：肺癌診斷與遠端醫療平台的整合是一種加速發展的趨勢，它能夠進行遠距會診、診斷影像解讀和後續隨訪，從而改善獲得專家意見的機會，並減少就醫的地域障礙，這對服務不足的人群尤其重要。

這些趨勢正在顯著地重塑肺癌診斷市場，使其朝向侵入性更小、更準確、高度個人化的診斷方法發展，同時提高可及性和效率，最終提高早期發現率，並帶來更有效、更有針對性的治療策略。

肺癌診斷市場近期趨勢

近年來，肺癌診斷市場經歷了幾個關鍵性的發展趨勢，這主要得益於全球對早期檢測的重視、分子生物學的進步以及數位技術的融合應用。這些變革旨在提高診斷準確度、降低侵入性並改善患者預後。

  • 低劑量 CT篩檢的興起：一項關鍵進展是全球範圍內採用和接受低劑量電腦斷層掃描 (LDCT) 作為高危險群肺癌篩檢的標準，與傳統方法相比，可更早發現更小、更易治療的腫瘤，並顯著提高生存率。
  • 液態切片的進展：近期發展凸顯了液態切片的快速進步和日益成長的臨床效用。這項非侵入性技術能夠從血液樣本中檢測循環腫瘤DNA（ctDNA）、循環性腫瘤細胞（CTC）和其他生物標記物，從而實現早期診斷、個人化治療選擇和復發監測。
  • 人工智慧在放射學中的應用：近年來，人工智慧（AI）和機器學習演算法在診斷放射成像領域的應用日益廣泛。人工智慧工具能夠幫助放射科醫師更準確、有效率地識別和表徵可疑的肺結節，從而減少假陽性結果並改善診斷流程。
  • 擴展的分子譜分析：肺癌的綜合分子譜分析取得了顯著進展，從單基因突變擴展到多基因panel和次世代定序（NGS），這提供了更詳細的腫瘤基因圖譜，對於指南精準腫瘤學中的標靶治療和免疫治療至關重要。
  • 新型生物標記開發：近期趨勢包括發現和檢驗新型診斷和預後生物標記，包括特定蛋白質、微型RNA和表觀遺傳標記物，透過各種平台檢測這些標記有助於早期診斷、預測治療反應和監測疾病進展，從而增強個人化治療。

這些治療方法正在顯著影響肺癌診斷市場，推動人們轉向更積極的篩檢、更少侵入性的診斷方法以及基於詳細分子資訊的高度個人化的治療方法，最終改善患者的護理和生存率。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球肺癌診斷市場（按類型分類）

  • 概述
  • 吸引力分析：按類型
  • 免疫測定：趨勢與預測（2019-2031）
  • 流式細胞技術：趨勢與預測（2019-2031）
  • 快速檢測：趨勢與預測（2019-2031）
  • 分子檢測：趨勢與預測（2019-2031）
  • 組織晶片：趨勢與預測（2019-2031）
  • 循環性腫瘤細胞：趨勢與預測（2019-2031）
  • 藥物診斷：趨勢與預測（2019-2031）
  • 生物標記：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

第5章 全球肺癌診斷市場（依應用分類）

  • 概述
  • 吸引力分析：依目的
  • 產業：趨勢與預測（2019-2031）
  • 醫療保健：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

第6章 區域分析

  • 概述
  • 全球肺癌診斷市場（按地區分類）

7. 北美肺癌診斷市場

  • 概述
  • 北美肺癌診斷市場按類型分類
  • 北美肺癌診斷市場按應用領域分類
  • 美國肺癌診斷市場
  • 墨西哥肺癌診斷市場
  • 加拿大肺癌診斷市場

8. 歐洲肺癌診斷市場

  • 概述
  • 歐洲肺癌診斷市場按類型分類
  • 歐洲肺癌診斷市場按應用領域分類
  • 德國肺癌診斷市場
  • 法國肺癌診斷市場
  • 西班牙肺癌診斷市場
  • 義大利肺癌診斷市場
  • 英國肺癌診斷市場

9. 亞太地區肺癌診斷市場

  • 概述
  • 亞太地區肺癌診斷市場（按類型分類）
  • 亞太地區肺癌診斷市場按應用分類
  • 日本肺癌診斷市場
  • 印度肺癌診斷市場
  • 中國肺癌診斷市場
  • 韓國肺癌診斷市場
  • 印尼肺癌診斷市場

第10章 世界其他地區（ROW）肺癌診斷市場

  • 概述
  • ROW肺癌診斷市場按類型分類
  • ROW肺癌診斷市場按應用領域分類
  • 中東肺癌診斷市場
  • 南美洲肺癌診斷市場
  • 非洲肺癌診斷市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 透過申請獲得發展機會
  • 全球肺癌診斷市場新興趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併、協議、合作關係和合資企業

第13章：價值鏈中主要企業的概況

  • 競爭分析
  • Roche Diagnostics
  • BioMerieux
  • Qiagen
  • Advpharma
  • AIT Austrian Institute of Technology
  • Courtagen Life Sciences
  • DiagnoCure
  • BioMark Diagnostics
  • Mayo Clinic
  • HalioDx SAS

第14章附錄

  • 圖表清單
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global lung cancer diagnostic market looks promising with opportunities in the industrial and healthcare markets. The global lung cancer diagnostic market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the increasing global lung cancer incidence rates, the rising adoption of non-invasive liquid biopsies, and the growing implementation of ai-driven imaging technologies.

  • Lucintel forecasts that, within the type category, molecular assay is expected to witness the highest growth over the forecast period.
  • Within the application category, healthcare is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is currently at the cusp of a major transformation, fueled by advancements in genomics, imaging, and artificial intelligence. These emerging trends are significantly improving the accuracy, accessibility, and personalization of lung cancer diagnosis, ultimately leading to better patient outcomes.

  • Liquid Biopsy Adoption: Liquid biopsy, which involves analyzing blood for circulating tumor DNA (ctDNA) or other biomarkers, is a rapidly emerging trend. This non-invasive method offers a less burdensome alternative to tissue biopsies, enabling earlier detection, monitoring treatment response, and identifying resistance mechanisms, thus revolutionizing patient management.
  • AI and Machine Learning in Imaging: The integration of Artificial Intelligence (AI) and Machine Learning (ML) into diagnostic imaging (CT scans, X-rays) is a powerful trend. AI algorithms enhance the detection of subtle nodules, reduce false positives, and improve diagnostic accuracy, assisting radiologists in efficiently analyzing large volumes of imaging data for early and precise diagnosis.
  • Multi-Omics Profiling: There's an increasing trend towards multi-omics profiling, combining genomic, proteomic, and metabolomic data for comprehensive lung cancer diagnosis. This holistic approach identifies complex molecular signatures, leading to more precise stratification of patients and guiding highly individualized therapeutic strategies for superior outcomes.
  • Point-of-Care Diagnostics: The development of rapid, portable, and easy-to-use Point-of-Care (POC) diagnostic devices is an emerging trend, especially for biomarker detection. These devices enable quick screening and initial diagnosis in non-specialized settings, improving accessibility to diagnostics in remote or resource-limited areas.
  • Integration with Telemedicine: The integration of lung cancer diagnostics with telemedicine platforms is an accelerating trend. This allows for remote consultation, interpretation of diagnostic images, and follow-up, improving access to specialist opinions and reducing geographical barriers to care, particularly vital for underserved populations.

These trends are profoundly reshaping the lung cancer diagnostic market by shifting towards less invasive, more accurate, and highly personalized diagnostic approaches. They are also improving accessibility and efficiency, ultimately enhancing early detection rates and guiding more effective, targeted treatment strategies.

Recent Developments in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market has witnessed several pivotal recent developments, primarily driven by a global push for early detection, advancements in molecular biology, and the integration of digital technologies. These changes aim to enhance diagnostic accuracy, reduce invasiveness, and improve patient outcomes.

  • Rise of Low-Dose CT Screening: A significant development is the increasing global adoption and endorsement of Low-Dose Computed Tomography (LDCT) as the standard for lung cancer screening in high-risk individuals. This has led to earlier detection of smaller, more treatable tumors, significantly improving survival rates compared to traditional methods.
  • Advancements in Liquid Biopsy: Recent developments highlight the rapid progress and increasing clinical utility of liquid biopsy. This non-invasive technology allows for the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from blood samples, enabling early diagnosis, personalized treatment selection, and monitoring for recurrence.
  • Integration of AI in Radiology: A key recent development is the growing integration of Artificial Intelligence (AI) and machine learning algorithms into radiological imaging. AI-powered tools assist radiologists in identifying and characterizing suspicious lung nodules more accurately and efficiently, reducing false positives and improving diagnostic workflows.
  • Expanded Molecular Profiling: There's a notable development in the comprehensive molecular profiling of lung cancer, moving beyond single gene mutations to include multi-gene panels and next-generation sequencing (NGS). This provides a more detailed genetic blueprint of the tumor, crucial for guiding targeted therapies and immunotherapies in precision oncology.
  • Development of Novel Biomarkers: Recent developments include the discovery and validation of new diagnostic and prognostic biomarkers. These include specific proteins, microRNAs, and epigenetic markers, which can be detected through various platforms to aid in early diagnosis, predict treatment response, and monitor disease progression, enhancing personalized care.

These developments are profoundly impacting the lung cancer diagnostic market by fostering a shift towards more proactive screening, less invasive diagnostic methods, and highly personalized treatment approaches based on detailed molecular information, ultimately improving patient care and survival rates.

Strategic Growth Opportunities in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market offers substantial strategic growth opportunities across various key application areas, driven by the increasing global burden of lung cancer, continuous technological innovations, and a rising emphasis on early detection and personalized medicine. Identifying and capitalizing on these segments is crucial for market players to achieve sustainable growth.

  • Early Lung Cancer Screening Programs: The expansion of population-based lung cancer screening programs using LDCT, particularly for high-risk individuals (e.g., heavy smokers), presents a significant growth opportunity. This drives demand for imaging equipment, AI-powered diagnostic software, and associated pathology services for nodule work-up.
  • Personalized Medicine and Biomarker Testing: The accelerating shift towards personalized medicine in oncology creates a robust growth avenue. The demand for comprehensive biomarker testing (e.g., EGFR, ALK, PD-L1, KRAS) using molecular diagnostics (NGS, PCR) and liquid biopsies is paramount for guiding targeted therapies and immunotherapies.
  • Post-Treatment Monitoring and Recurrence Detection: Providing diagnostic solutions for monitoring patients post-treatment and detecting early recurrence offers a strategic growth opportunity. Liquid biopsies, with their non-invasive nature, are increasingly valuable for serial monitoring of minimal residual disease and identifying emergent resistance mutations, guiding subsequent treatment decisions.
  • Point-of-Care Diagnostics in Primary Care: The development and deployment of accessible point-of-care (POC) diagnostic tests, particularly for early symptom assessment or initial biomarker screening in primary care settings, presents a valuable opportunity. This can facilitate quicker referrals and reduce diagnostic delays, especially in underserved areas.
  • Research and Drug Development Partnerships: Collaborating with pharmaceutical and biotechnology companies for companion diagnostics and clinical trial support offers a high-value, strategic growth opportunity. Developing diagnostic assays that identify patients most likely to respond to novel targeted therapies or immunotherapies is critical for drug development and regulatory approval.

These opportunities are profoundly impacting the lung cancer diagnostic market by shifting focus towards proactive screening, precision-based treatment guidance, continuous monitoring, and accessible diagnostic tools, thus expanding the market's reach and value across the entire patient journey.

Lung Cancer Diagnostic Market Driver and Challenges

The lung cancer diagnostic market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. Understanding these primary drivers that propel market expansion and the significant challenges that may impede its growth is crucial for strategic decision-making by industry stakeholders.

The factors responsible for driving the lung cancer diagnostic market include:

1. Rising Incidence of Lung Cancer: The increasing global incidence of lung cancer, primarily due to factors like smoking, air pollution, and an aging population, is the most significant market driver. This escalating disease burden directly translates to a heightened demand for effective diagnostic tools and early detection strategies.

2. Growing Awareness for Early Detection: Increased public and physician awareness regarding the benefits of early lung cancer detection and the availability of screening programs (like LDCT) is a major driver. Public health campaigns and educational initiatives encourage high-risk individuals to undergo screening, boosting diagnostic volumes.

3. Technological Advancements in Diagnostics: Continuous innovations in diagnostic technologies, including high-resolution imaging, liquid biopsy, next-generation sequencing, and AI-powered analytics, are propelling market growth. These advancements lead to more accurate, less invasive, and faster diagnostic results, driving adoption.

4. Shift Towards Precision Medicine: The paradigm shift towards precision medicine in oncology significantly drives the demand for comprehensive diagnostic testing. Identifying specific genetic mutations and biomarkers is crucial for selecting targeted therapies and immunotherapies, leading to personalized and more effective treatment outcomes.

5. Favorable Reimbursement Policies: The increasing coverage and reimbursement for lung cancer screening (e.g., LDCT) and advanced molecular diagnostic tests by government and private payers are crucial market drivers. Favorable reimbursement policies enhance accessibility and affordability, encouraging broader adoption of diagnostic services.

Challenges in the lung cancer diagnostic market are:

1. High Cost of Advanced Diagnostics: The significant cost associated with advanced diagnostic technologies, such as comprehensive molecular profiling (NGS) and liquid biopsies, presents a major challenge. This can limit accessibility, particularly in developing regions or for patients without adequate insurance coverage, hindering widespread adoption.

2. Lack of Skilled Professionals: There is a global shortage of highly skilled healthcare professionals, including radiologists, pulmonologists, and molecular pathologists, trained in interpreting complex diagnostic tests and managing screening programs. This scarcity can impact the efficient implementation and scalability of advanced diagnostic services.

3. False Positives and Overdiagnosis: Lung cancer screening, particularly with LDCT, can lead to false-positive findings, necessitating additional invasive procedures and causing patient anxiety. The risk of overdiagnosis (detecting indolent tumors that would not have caused harm) also presents a challenge, requiring careful patient selection and management strategies.

The lung cancer diagnostic market is experiencing robust expansion, primarily fueled by the increasing global incidence of lung cancer, growing awareness for early detection, and rapid technological advancements, especially in precision medicine. However, significant challenges such as the high cost of advanced diagnostics, a shortage of skilled professionals, and concerns regarding false positives and overdiagnosis necessitate continuous innovation and strategic solutions to ensure equitable access and optimal patient care.

List of Lung Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies lung cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer diagnostic companies profiled in this report include-

  • Roche Diagnostics
  • BioMerieux
  • Qiagen
  • Advpharma
  • AIT Austrian Institute of Technology
  • Courtagen Life Sciences
  • DiagnoCure
  • BioMark Diagnostics
  • Mayo Clinic
  • HalioDx SAS

Lung Cancer Diagnostic Market by Segment

The study includes a forecast for the global lung cancer diagnostic market by type, application, and region.

Lung Cancer Diagnostic Market by Type [Value from 2019 to 2031]:

  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics
  • Biomarkers
  • Others

Lung Cancer Diagnostic Market by Application [Value from 2019 to 2031]:

  • Industrial
  • Healthcare
  • Others

Lung Cancer Diagnostic Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is undergoing a transformative period, driven by advancements in early detection, precision medicine, and the integration of cutting-edge technologies. Recent developments focus on improving screening efficacy, developing non-invasive diagnostic tools, and identifying specific biomarkers to enable more personalized and effective treatment strategies for patients globally.

  • United States: The U.S. market is heavily influenced by updated screening guidelines recommending low-dose CT for high-risk individuals. Recent developments include increased adoption of liquid biopsy for molecular profiling, growing interest in AI-powered image analysis to enhance diagnostic accuracy, and a strong push towards integrating these advanced diagnostics into clinical practice for personalized treatment.
  • China: China lung cancer diagnostic market is rapidly expanding, with significant government support for early screening programs. Recent developments include widespread adoption of LDCT, increasing research and application of liquid biopsy for early detection and treatment monitoring, and a growing emphasis on AI-assisted diagnostics to manage the high volume of cases and improve efficiency.
  • Germany: Germany has recently approved lung cancer screening as a benefit for statutory health insurance, signaling a major development. This will drive increased LDCT utilization. Recent developments also emphasize precision medicine, with growing use of molecular diagnostics for biomarker testing, alongside strong quality assurance requirements for screening programs, aligning with European healthcare standards.
  • India: India lung cancer diagnostic market is growing due to increasing incidence and a push for early detection. Recent developments include initiatives like "LungLife" screening programs, increased adoption of LDCT, and a focus on identifying India-specific high-risk populations for targeted screening, with ongoing research into cost-effective blood-based biomarkers.
  • Japan: Japan lung cancer diagnostic market is marked by technological sophistication and a focus on automation. Recent developments include extensive research and application of AI in analyzing CT images for nodule detection and characterization, with ultra-lightweight AI models being developed for accessible diagnostics, enhancing early detection efforts and reducing radiologist workload.

Features of the Global Lung Cancer Diagnostic Market

  • Market Size Estimates: Lung cancer diagnostic market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Lung cancer diagnostic market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Lung cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the lung cancer diagnostic market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the lung cancer diagnostic market by type (immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, biomarkers, and others), application (industrial, healthcare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Lung Cancer Diagnostic Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Immunoassays: Trends and Forecast (2019-2031)
  • 4.4 Flow Cytometry: Trends and Forecast (2019-2031)
  • 4.5 Rapid Tests: Trends and Forecast (2019-2031)
  • 4.6 Molecular Assays: Trends and Forecast (2019-2031)
  • 4.7 Tissue Arrays: Trends and Forecast (2019-2031)
  • 4.8 Circulating Tumor Cells: Trends and Forecast (2019-2031)
  • 4.9 Pharmacodiagnostics: Trends and Forecast (2019-2031)
  • 4.10 Biomarkers: Trends and Forecast (2019-2031)
  • 4.11 Others: Trends and Forecast (2019-2031)

5. Global Lung Cancer Diagnostic Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Industrial: Trends and Forecast (2019-2031)
  • 5.4 Healthcare: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Lung Cancer Diagnostic Market by Region

7. North American Lung Cancer Diagnostic Market

  • 7.1 Overview
  • 7.2 North American Lung Cancer Diagnostic Market by Type
  • 7.3 North American Lung Cancer Diagnostic Market by Application
  • 7.4 United States Lung Cancer Diagnostic Market
  • 7.5 Mexican Lung Cancer Diagnostic Market
  • 7.6 Canadian Lung Cancer Diagnostic Market

8. European Lung Cancer Diagnostic Market

  • 8.1 Overview
  • 8.2 European Lung Cancer Diagnostic Market by Type
  • 8.3 European Lung Cancer Diagnostic Market by Application
  • 8.4 German Lung Cancer Diagnostic Market
  • 8.5 French Lung Cancer Diagnostic Market
  • 8.6 Spanish Lung Cancer Diagnostic Market
  • 8.7 Italian Lung Cancer Diagnostic Market
  • 8.8 United Kingdom Lung Cancer Diagnostic Market

9. APAC Lung Cancer Diagnostic Market

  • 9.1 Overview
  • 9.2 APAC Lung Cancer Diagnostic Market by Type
  • 9.3 APAC Lung Cancer Diagnostic Market by Application
  • 9.4 Japanese Lung Cancer Diagnostic Market
  • 9.5 Indian Lung Cancer Diagnostic Market
  • 9.6 Chinese Lung Cancer Diagnostic Market
  • 9.7 South Korean Lung Cancer Diagnostic Market
  • 9.8 Indonesian Lung Cancer Diagnostic Market

10. ROW Lung Cancer Diagnostic Market

  • 10.1 Overview
  • 10.2 ROW Lung Cancer Diagnostic Market by Type
  • 10.3 ROW Lung Cancer Diagnostic Market by Application
  • 10.4 Middle Eastern Lung Cancer Diagnostic Market
  • 10.5 South American Lung Cancer Diagnostic Market
  • 10.6 African Lung Cancer Diagnostic Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Lung Cancer Diagnostic Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Roche Diagnostics
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 BioMerieux
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Qiagen
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Advpharma
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 AIT Austrian Institute of Technology
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Courtagen Life Sciences
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 DiagnoCure
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 BioMark Diagnostics
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Mayo Clinic
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 HalioDx SAS
    • Company Overview
    • Lung Cancer Diagnostic Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Lung Cancer Diagnostic Market
  • Figure 2.1: Usage of Lung Cancer Diagnostic Market
  • Figure 2.2: Classification of the Global Lung Cancer Diagnostic Market
  • Figure 2.3: Supply Chain of the Global Lung Cancer Diagnostic Market
  • Figure 3.1: Driver and Challenges of the Lung Cancer Diagnostic Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Lung Cancer Diagnostic Market ($B) by Type
  • Figure 4.3: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Immunoassays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Flow Cytometry in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Rapid Tests in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Molecular Assays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.8: Trends and Forecast for Tissue Arrays in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.9: Trends and Forecast for Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.10: Trends and Forecast for Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.11: Trends and Forecast for Biomarkers in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 4.12: Trends and Forecast for Others in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.1: Global Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Lung Cancer Diagnostic Market ($B) by Application
  • Figure 5.3: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Industrial in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Healthcare in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Lung Cancer Diagnostic Market (2019-2031)
  • Figure 6.1: Trends of the Global Lung Cancer Diagnostic Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Lung Cancer Diagnostic Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 7.3: Forecast for the North American Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 7.4: North American Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 7.6: Forecast for the North American Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.1: European Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 8.3: Forecast for the European Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 8.4: European Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 8.6: Forecast for the European Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.1: APAC Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 9.3: Forecast for the APAC Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 9.4: APAC Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 9.6: Forecast for the APAC Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.1: ROW Lung Cancer Diagnostic Market by Type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Lung Cancer Diagnostic Market ($B) by Type (2019-2024)
  • Figure 10.3: Forecast for the ROW Lung Cancer Diagnostic Market ($B) by Type (2025-2031)
  • Figure 10.4: ROW Lung Cancer Diagnostic Market by Application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Lung Cancer Diagnostic Market ($B) by Application (2019-2024)
  • Figure 10.6: Forecast for the ROW Lung Cancer Diagnostic Market ($B) by Application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Lung Cancer Diagnostic Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Lung Cancer Diagnostic Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Lung Cancer Diagnostic Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Type
  • Figure 12.2: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Application
  • Figure 12.3: Growth Opportunities for the Global Lung Cancer Diagnostic Market by Region
  • Figure 12.4: Emerging Trends in the Global Lung Cancer Diagnostic Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Lung Cancer Diagnostic Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Lung Cancer Diagnostic Market by Region
  • Table 1.3: Global Lung Cancer Diagnostic Market Parameters and Attributes
  • Table 3.1: Trends of the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 3.2: Forecast for the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Lung Cancer Diagnostic Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.4: Trends of Immunoassays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.5: Forecast for Immunoassays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.6: Trends of Flow Cytometry in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.7: Forecast for Flow Cytometry in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.8: Trends of Rapid Tests in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.9: Forecast for Rapid Tests in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.10: Trends of Molecular Assays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.11: Forecast for Molecular Assays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.12: Trends of Tissue Arrays in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.13: Forecast for Tissue Arrays in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.14: Trends of Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.15: Forecast for Circulating Tumor Cells in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.16: Trends of Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.17: Forecast for Pharmacodiagnostics in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.18: Trends of Biomarkers in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.19: Forecast for Biomarkers in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 4.20: Trends of Others in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 4.21: Forecast for Others in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Lung Cancer Diagnostic Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.4: Trends of Industrial in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.5: Forecast for Industrial in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.6: Trends of Healthcare in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.7: Forecast for Healthcare in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Lung Cancer Diagnostic Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.1: Trends of the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.2: Forecast for the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Lung Cancer Diagnostic Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Lung Cancer Diagnostic Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Lung Cancer Diagnostic Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Lung Cancer Diagnostic Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.1: Trends of the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.2: Forecast for the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Lung Cancer Diagnostic Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Lung Cancer Diagnostic Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Lung Cancer Diagnostic Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.1: Trends of the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.2: Forecast for the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Lung Cancer Diagnostic Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Lung Cancer Diagnostic Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Lung Cancer Diagnostic Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.1: Trends of the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.2: Forecast for the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Lung Cancer Diagnostic Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Lung Cancer Diagnostic Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Lung Cancer Diagnostic Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Lung Cancer Diagnostic Market (2019-2031)
  • Table 11.1: Product Mapping of Lung Cancer Diagnostic Suppliers Based on Segments
  • Table 11.2: Operational Integration of Lung Cancer Diagnostic Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Lung Cancer Diagnostic Revenue
  • Table 12.1: New Product Launches by Major Lung Cancer Diagnostic Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Lung Cancer Diagnostic Market